Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow

robot
Abstract generation in progress

The Non-Muscle Invasive Bladder Cancer (NMIBC) market is projected to grow by $1 billion, reaching $4.82 billion by 2030, led by companies like Johnson & Johnson, Janssen Research & Development, and Merck & Co. This growth is primarily fueled by early diagnosis, increased use of transurethral resection, immunotherapy, chemotherapy, and advancements in personalized medicine. North America currently leads the market, with Asia-Pacific anticipated to show the fastest growth in the coming decade.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin